• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

    11/14/24 4:05:31 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCRX alert in real time by email
    SC 13G/A 1 ef20038300_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

    TScan Therapeutics, Inc.
    (Name of Issuer)

    Voting Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

    89854M101
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages
    Page 1 of 10 Pages
    Exhibit Index: Page 9



    CUSIP No. 89854M101
    Page 2 of 10 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    K2 HealthVentures Equity Trust LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    5,324,144 (1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    5,324,144 (1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,324,144 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    9.985% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    (1) See Items 2 and 4


    CUSIP No. 89854M101
    Page 3 of 10 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Parag Shah
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    5,324,144 (1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    5,324,144 (1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,324,144 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    9.985% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC, IN
     
     
     
     
    (1) See Items 2 and 4


    CUSIP No. 89854M101
    Page 4 of 10 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Anup Arora
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    5,324,144 (1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    5,324,144 (1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,324,144 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    9.985% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC, IN
     
     
     
     
    (1) See Items 2 and 4


    CUSIP No. 89854M101
    Page 5 of 10 Pages
    Item 1(a).
    Name of Issuer:

    TScan Therapeutics, Inc. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    830 Winter Street, Waltham, MA 02451

    Item 2(a).
    Name of Person Filing:

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):


    i.
    K2 HealthVentures Equity Trust LLC (“K2HV Equity”);

    ii.
    Parag Shah (“Mr. Shah”); and

    iii.
    Anup Arora (“Mr. Arora”).

    This Statement on Schedule 13G relates to 700,000 shares of Common Stock (as defined herein) that K2HV Equity holds directly and 4,624,144 shares of Common Stock that K2HV Equity has the right to acquire within 60 days upon conversion of up to $50,000,000 of convertible term loans that the Reporting Persons, through a lender affiliate, agreed to extend to the Issuer (the “Convertible Term Loans”), of which $30,000,000 is fully funded as of the date of this Schedule 13G (the “First Tranche”) and an additional uncommitted $20,000,000 may be funded at the discretion of the Reporting Persons (the “Third Tranche”). Pursuant to the terms of the loan and security agreement governing the Convertible Term Loans (the “Loan and Security Agreement”), the Reporting Persons may elect at any time following the September 9, 2022 closing date and prior to the repayment in full of the Convertible Term Loans to convert any portion of the principal amount of the Convertible Term Loans then outstanding into shares of Common Stock, at the then-applicable conversion price and subject to the Blockers (as defined herein).  The current conversion price of the fully-funded First Tranche is $4.785 per share (the conversion price for the Third Tranche will be a price equal to 140% of the Lowest Trailing Three-Day VWAP (as defined in the Loan and Security Agreement) during the 30 day period immediately preceding funding of the Third Tranche).  Pursuant to the terms of the Loan and Security Agreement, the Reporting Persons may not convert any portion of the Convertible Term Loans into shares of Common Stock to the extent that, upon conversion, the beneficial ownership of the Reporting Persons (including any affiliates and Section 13(d) “group” members) would exceed 9.985% of the total number of shares of Common Stock outstanding (the “9.985% Cap”) or 19.99% of the total number of shares of Common Stock outstanding (the “19.99% Cap” and, together with the 9.985% Cap, the “Blockers”).  The Reporting Persons may waive the 9.985% Cap upon 61 days’ prior written notice to the Issuer, but may not waive the 19.99% Cap.

    K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it holds directly and has the right to acquire within 60 days upon conversion of the Convertible Term Loans.  Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity holds directly and has the right to acquire within 60 days upon conversion of the Convertible Term Loans.

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116.

    Item 2(c).
    Citizenship:

    K2HV Equity is a Delaware limited liability company.  Each of Mr. Shah and Mr. Arora is a citizen of the United States of America.

    Item 2(d).
    Titles of Classes of Securities:

    Voting Common Stock, $0.0001 par value per share (“Common Stock”)


    CUSIP No. 89854M101
    Page 6 of 10 Pages
    Item 2(e).
    CUSIP Number:

    89854M101

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

    This Item 3 is not applicable.

    Item 4.
    Ownership:

    Item 4(a).
    Amount Beneficially Owned:

    As of September 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of 5,324,144 shares of Common Stock.  This amount includes 700,000 shares of Common Stock held directly by K2HV Equity and 4,624,144 shares of Common Stock that K2HV Equity has the right to acquire within 60 days upon conversion of the Convertible Term Loans, subject to the Blockers.

    Item 4(b).
    Percent of Class:

    As of September 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of approximately 9.985% of the shares of Common Stock outstanding.

    The percentages set forth herein are calculated based on the sum of: (i) 48,697,282 shares of Common Stock outstanding as of August 8, 2024, as reported in the Issuer’s quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2024, and (ii) 4,624,144 shares of Common Stock that the Reporting Persons currently have the right to acquire within 60 days upon conversion of the Convertible Term Loans, subject to the Blockers, which shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

    Item 4(c).
    Number of Shares as to which such person has:

    K2HV Equity, Mr. Shah and Mr. Arora
     
    (i) Sole power to vote or direct the vote:
    0
    (ii) Shared power to vote or direct the vote:
    5,324,144
    (iii) Sole power to dispose or direct the disposition of:
    0
    (iv) Shared power to dispose or direct the disposition of:
    5,324,144

    Item 5.
    Ownership of Five Percent or Less of a Class.

    This Item 5 is not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.


    CUSIP No. 89854M101
    Page 7 of 10 Pages
    Item 9.
    Notice of Dissolution of Group.
     
    This Item 9 is not applicable.

    Item 10.
    Certification. (if filing pursuant to Rule 13d-1(c))

    By signing below each Reporting Person certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    CUSIP No. 89854M101
    Page 8 of 10 Pages
    SIGNATURE

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024
     
       
     
    K2 HEALTHVENTURES EQUITY TRUST LLC
         
     
    By:
    /s/ Anup Arora
     
    Name:
    Anup Arora
     
    Title:
    Managing Member
       
     
    PARAG SHAH
       
     
    By:
    /s/ Parag Shah
       
     
    ANUP ARORA
       
     
    By:
    /s/ Anup Arora


    CUSIP No. 89854M101
    Page 9 of 10 Pages
    EXHIBIT INDEX

    Exhibit
    Page No.
       
    A – Joint Filing Agreement
    10


    CUSIP No. 89854M101
    Page 10 of 10 Pages
    EXHIBIT A

    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Voting Common Stock of TScan Therapeutics, Inc., dated as of November 14, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

    Dated: November 14, 2024
     
       
     
    K2 HEALTHVENTURES EQUITY TRUST LLC
         
     
    By:
    /s/ Anup Arora
     
    Name:
    Anup Arora
     
    Title:
    Managing Member
       
     
    PARAG SHAH
       
     
    By:
    /s/ Parag Shah
       
     
    ANUP ARORA
       
     
    By:
    /s/ Anup Arora



    Get the next $TCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRX

    DatePrice TargetRatingAnalyst
    5/16/2024$12.00Buy
    BTIG Research
    5/13/2024$11.00Buy
    Needham
    6/22/2023$8.00Outperform
    Wedbush
    12/16/2021$21.00Buy
    HC Wainwright & Co.
    8/13/2021Outperform
    Cowen & Co.
    8/10/2021$22.00Overweight
    Barclays
    8/10/2021$22.00Overweight
    Morgan Stanley
    8/10/2021$21.00Buy
    Jefferies
    More analyst ratings

    $TCRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by TScan Therapeutics Inc.

      10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:30:20 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:15:10 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TScan Therapeutics Inc.

      EFFECT - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/17/25 12:15:08 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

      WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries. "We are delighted to welcome Stephen to TScan at this stage of growth for the Company," said Gavin MacBeath, Ph.D., Chief Executive Officer.

      3/27/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T

      8/12/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

      WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization. "We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors

      4/8/24 8:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vice President, Finance Dworak Leiden

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:39 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Zdraveski Zoran

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:41 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Macbeath Gavin

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:52:57 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lynx1 Capital Management Lp bought $95,629 worth of shares (31,800 units at $3.01) and bought $290,140 worth of shares (100,000 units at $2.90) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/16/24 4:26:18 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $4,114 worth of shares (947 units at $4.34) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      11/19/24 4:26:43 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Klencke Barbara bought $26,450 worth of Voting Common Stock (5,000 units at $5.29), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      9/24/24 5:26:24 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on TScan Therapeutics with a new price target

      BTIG Research initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $12.00

      5/16/24 7:35:53 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on TScan Therapeutics with a new price target

      Needham initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $11.00

      5/13/24 8:33:06 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on TScan Therapeutics with a new price target

      Wedbush initiated coverage of TScan Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/22/23 7:30:31 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Financials

    Live finance-specific insights

    See more
    • TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

      All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) --  TScan Th

      2/26/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible t

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and i

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:40:11 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:05:31 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 3:05:59 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported fina

      5/6/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

      WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually. Poster Presentation Details: Title: CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell TransplantationAuthors: Kostadin O Petrov, Stephen P Carroll, Kenneth L Jahan, R

      4/28/25 4:53:52 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TScan Th

      3/31/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care